Pierce Christopher
SEC CIK 1824631 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | EVP, Chief of Business Oper | 3,750 | — | $708.5K | 2 | 2021-09-02 | 2021-09-02 |
Most active insiders at PRLD, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Bonita David P | Dir, 10% | $12.50M | — |
| 2 | ORBIMED ADVISORS LLC | Dir, 10% | $12.50M | — |
| 3 | Huang Jane | Pres, CMO | — | — |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 10% | — | — |
Pierce Christopher made no open-market trades at PRLD in the last 12 months.
Transactions 2
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-09-07 | 2021-09-02 | PRLD | Prelude Therapeutics Inc | Pierce Christopher | EVP, Chief of Business Oper | S - Sale+OE | $41.68 | -17.0K | 3,750 | -82% | -$708.5K |
| D | 2021-09-07 | 2021-09-02 | PRLD | Prelude Therapeutics Inc | Pierce Christopher | EVP, Chief of Business Oper | M - OptEx | $12.85 | +17.0K | 20.8K | +453% | +$218.4K |
Purchase Sale Sale after option exercise All abbreviations